Last updated: July 20, 2026
LA JOLLA PHARMACEUTICAL COMPANY v. GLAND PHARMA LIMITED (2:22-cv-01754): Litigation Summary, Patent Claims, and Generic/Launch Risk
LA Jolla Pharmaceutical Co. (LJPC) sued Gland Pharma Ltd. (Gland) in the District of New Jersey (case no. 2:22-cv-01754) in an ANDA-related patent infringement posture. The litigation record is not provided here in a way that allows identification of the specific asserted patents, Orange Book-listed products, ANDA filing date, Paragraph IV timing, claim construction outcomes, claim chart details, or settlement/dismissal terms. Without those case-specific filings and docket events, a complete and accurate litigation summary and patent-strength analysis cannot be produced.
What patents are asserted in LA JOLLA PHARMACEUTICAL COMPANY v. GLAND PHARMA LIMITED 2:22-cv-01754?
No asserted-patent identifiers (patent numbers), claims, or Orange Book reference listings are included in the provided input. Without the asserted-patent list from the complaint or amended pleadings, the patent estate cannot be mapped to claim scope, expiration, or infringement theories.
Which Orange Book patents are implicated by the asserted infringement claims?
No Orange Book listing details (listed patents, expiration dates, regulatory exclusivities, FDA application numbers) are included in the provided input.
Are method-of-use, formulation, or process patents at issue?
The provided input does not specify whether the case asserts:
- method-of-use claims,
- formulation/dosage form claims,
- manufacturing/process claims, or
- device or ancillary claims.
What does the complaint allege about Gland’s ANDA filing and Paragraph IV notice?
The provided input does not include:
- the ANDA applicant/labeler,
- the reference product and strength,
- the ANDA submission date,
- the Paragraph IV notice date,
- the notice contents,
- or the FDA approval status.
When did Paragraph IV notice occur relative to FDA review milestones?
No Paragraph IV timeline events are included, so launch-eligibility and “at-risk” window cannot be calculated.
Is the suit framed as direct infringement, induced infringement, or willful infringement?
No pleadings excerpt is included, so the infringement theory and intent allegations cannot be summarized.
What is the procedural posture of 2:22-cv-01754: motions, claim construction, and trial scheduling?
The provided input contains no docket events, court orders, or motion results. As a result, this section cannot accurately cover:
- motions to dismiss,
- venue or jurisdiction challenges,
- transfer motions,
- preliminary injunction requests,
- claim construction (Markman) outcomes,
- summary judgment rulings,
- Daubert decisions,
- or trial/ITC-related scheduling.
Has the court issued a preliminary injunction or denial?
No injunction status is provided.
Were any patents found invalid or not infringed at the pleadings or summary judgment stage?
No ruling outcomes are provided.
How do courts in ANDA cases evaluate non-infringement and invalidity arguments in LJPC v. Gland?
A litigation-standard discussion without case-specific argument content would not be a “summary and analysis” of this case. The input provides no actual argument positions, expert reports, claim construction positions, or cited prior art.
What claim-construction terms drive infringement/non-infringement here?
No claim construction record is included.
What prior art and anticipation/obviousness themes were asserted?
No prior art references or invalidity grounds are provided.
When does exclusivity end and when could a generic launch occur based on this case?
No dates are provided (patent expirations, regulatory exclusivity end dates, consent decree terms, or stay expirations). Without:
- the asserted patent expiration set,
- any statutory exclusivity,
- any settlement stay,
- any FDA tentative approval/approval timing,
launch timing cannot be analyzed.
Does this case trigger a 30-month stay or another statutory pause?
No ANDA and Orange Book eligibility details are included.
What launch risk remains if the case is stayed or settled?
No settlement or dismissal terms are provided.
What settlements or dismissals occurred in LA JOLLA PHARMACEUTICAL COMPANY v. GLAND PHARMA LIMITED (2:22-cv-01754)?
No settlement agreement, consent order, stipulation of dismissal, covenant-not-to-sue, or license terms are included in the provided input. Without those, the litigation outcome cannot be stated.
Was there a dismissal with prejudice, without prejudice, or a partial dismissal?
No dismissal information is provided.
Were there licensing deals or side agreements affecting FDA approval timing?
No licensing terms are provided.
How does this litigation affect Gland Pharma’s competitive position for the reference product?
No product identification (reference drug, strength, dosage form) and no commercial context (who else is approved, who is at-risk, who is already marketing) is provided.
Which competitors are also positioned for market entry?
No competitor list or ANDA paragraph-IV landscape is provided.
Is Gland currently approved, tentative-approved, or blocked pending this case?
No FDA approval or approval status is provided.
Key Takeaways
- This input includes only the caption-style identification of the case number and parties.
- A litigation summary and patent/legal analysis requires the case record: asserted patents, complaint allegations, docket events, motion orders, claim construction, trial outcomes, and settlement or dismissal terms.
- Those case-specific details are not present in the provided information, so a complete and accurate summary cannot be produced.
FAQs
- What are the asserted patent numbers in 2:22-cv-01754?
- Did LJPC seek a preliminary injunction against Gland in this case, and what was the outcome?
- Which Orange Book-listed patents for the reference product were attacked via Paragraph IV?
- Was the case resolved by settlement, consent judgment, or dismissal, and what were the terms?
- What is the impact of the ruling or settlement on FDA ANDA approval timing and launch eligibility?
References
No sources are provided in the input.
